My Companies
Notification
Account
Log Out
Login
Gland Pharma signed an MSA with an unnamed global pharmaceutical company covering 55 sterile-injectable SKUs across three sites. Following two-year technology transfers, revenues are expected from 2029, with annualized potential of approximately USD 90–100 million once fully commercialized.
Gland Pharma Schedules UTI, Ashmore And Motilal Oswal Investor Meetings
Gland Pharma Secures USFDA Approval For Sugammadex Generic Injection